New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2012
10:20 EDTEA, TNB, SNCR, SYNC, SIGA, RHHBY, NCMI, MAKO, ERJ, EP, BP, ACMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AECOM Technology (ACM) downgraded to Underperform from Buy at BofA/Merrill... BP (BP) downgraded to Underweight from Equal Weight at Barclays... El Paso (EP) downgraded to Underweight from Neutral at Atlantic Equities... Embraer (ERJ) downgraded to Neutral from Buy at Citigroup... Mako Surgical (MAKO) downgraded to Neutral from Buy at Mizuho... National CineMedia (NCMI) downgraded to In-Line from Outperform at Imperial Capital... Roche (RHHBY) downgraded to Neutral from Overweight at JPMorgan... SIGA Technologies (SIGA) downgraded to Sector Perform from Outperform at RBC Capital... Synacor (SYNC) downgraded to Underperform from Buy at BofA/Merrill... Synchronoss (SNCR) downgraded to Market Perform from Outperform at Wells Fargo... Thomas & Betts (TNB) downgraded to Neutral from Outperform at RW Baird... Electronic Arts (EA) downgraded to Market Perform from Outperform at William Blair.
News For ACM;BP;EP;ERJ;MAKO;NCMI;RHHBY;SIGA;SYNC;SNCR;TNB;EA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
09:50 EDTACMAECOM Technology to host special shareholder meeting
Subscribe for More Information
07:44 EDTBPExxon, Shell behind rivals in lowering greenhouse gas emissions, WSJ reports
Subscribe for More Information
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
17:24 EDTACMS&P announces changes to the S&P MidCap 400 and S&P SmallCap 600 indices
Subscribe for More Information
06:36 EDTBPSaudi Arabia content to let oil prices stay low, Reuters reports
Subscribe for More Information
October 12, 2014
13:53 EDTBPKuwaiti Minister says OPEC unlikely to cut production, WSJ says
Subscribe for More Information
13:45 EDTBPSaudis take aggressive oil measures in Europe, WSJ says
Subscribe for More Information
October 10, 2014
10:01 EDTEAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:05 EDTBPBP begins $1.1B North Sea project, Bloomberg says
BP CEO Bob Dudley said that the company is poised to begin a project worth close to $1.1B in the North Sea this month, which is anticipated to supply oil and gas into the next ten years, according to Bloomberg, citing comments from Dudley. Reference Link
07:59 EDTEAElectronic Arts upgraded to Buy from Hold at Benchmark Co.
Benchmark Co. upgraded Electronic Arts to Buy with a $42.50 price target saying the company's upcoming Q2 results will likely beat expectations and drive share upside.
October 9, 2014
17:14 EDTERJEmbraer breaks ground on 500/450 assembly facility
Subscribe for More Information
10:41 EDTACMHigh option volume stocks
Subscribe for More Information
October 8, 2014
12:32 EDTSIGAPharmAthene announces court partially lifts stay of litigation against SIGA
Subscribe for More Information
11:31 EDTRHHBYFDA grants priority review for Genentech's Lucentis
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. FDA has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7M Americans. The FDA confirmed action date is February 6, 2015. The sBLA was submitted August 7 to address the unmet need for approved ocular medications for the treatment of diabetic retinopathy. If approved by the FDA, Lucentis could be the first eye medicine available for diabetic retinopathy patients. The submission is based on results of the RISE and RIDE Phase III trials in which meaningful improvements in the disease were observed in a clinically significant proportion of diabetic retinopathy patients treated with Lucentis at two years compared to patients treated with sham injections. Benefits of Lucentis treatment were maintained during year three of treatment. The safety in the RISE and RIDE Phase III trials was consistent with previous studies.
10:55 EDTRHHBYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
10:38 EDTACMHigh option volume stocks
High option volume stocks: FRAN RMTI ACM CY CLNY SMH BEAV SIG CTB DUG SHLD
09:12 EDTSYNCSynacor partners with Pac-12 Networks
Pac-12 Networks, the multiplatform media and content company wholly owned by the 12 universities of the Pac-12 Conference, has partnered with Synacor, to launch its Pac-12 Now TV Everywhere service for Pac-12 students living in on campus housing. Synacor provides the TV Everywhere authentication and authorization, extending, via proxy, the existing college student ID management system for each school. Students will use their same IDs to access Pac-12 programming as they do to access all their other online university services. And the relationship includes mobile—Synacor will integrate each campus with Pac-12 Now, the Pac-12 Networks' TV Everywhere app.
07:19 EDTRHHBYCBI to hold a conference
Subscribe for More Information
07:03 EDTACMAECOM awarded contract for Newtown Creek renewable natural gas project
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use